Circulation, Vol 53, 338-341, Copyright © 1976 by American Heart Association
PT Kuo, WC Fan, JB Kostis and K Hayase
The hypolipidemic effect of PAS-C-diet treatment was studied in 63 patients
with Types IIa and IIb hyperlipoproteinemia for 6-36 months. Serum lipids
and body weights of all patients were stabilized by a low
cholesterol-saturated fat-refined carbohydrate diet before the initiation
of an eight-week placebo-drug single-blind crossover study. During the
placebo period the plasma lipids levels, mean +/- SD: cholesterol 355 +/-
63.5 mg%, triglyceride 141 +/- 68.7 mg%, and LDL- cholesterol 279 +/- 56.8
mg% were lowered to 274 +/- 53.1 mg+, 98 +/- 40.6 mg%, and 209 +/- 52.9
mg%, respectively (P less than 0.001 in each instance), with 7.5-11.0 grams
of PAS-C/day given in one to three divided doses. In ten patients who have
completed three years of treatment similar results were obtained. They
showed no tendency to develop drug tolerance. Eight had watery diarrhea
during the initial period which promptly subsided with interruption of drug
therapy. Reintroduction of PAS-C in smaller dose (4.5 g/day) with gradual
increment to effective dosage level was tolerated by all. No hematologic,
hepatic, and ophthalmologic abnormalities were demonstrated by periodic
monitoring. The hypoplipidemic effect of the drug was found to be
diminished by alcohol and caloric excess.
ARTICLES
Combined para-aminosalicylic acid and dietary therapy in long-term control of hypercholesterolemia and hypertriglyceridemia (Types IIa and IIb hyperlipoproteinemia)
This article has been cited by other articles:
 |
|
 |
|
  R. I. Levy Drug Therapy of Hyperlipoproteinemia JAMA, May 24, 1976; 235(21): 2334 - 2336. [Abstract] [PDF]
|
|